A retrospective multicenter study assessing the infectious burden and associated impact on clinical outcome in patients with metastatic head and neck squamous cell carcinoma receiving pembrolizumab
Latest Information Update: 11 Jul 2022
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 11 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology